Compare EOG Resources Inc (EOG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs BIO-TECHNE Corp — how do they compare? EOG Resources Inc trades at $137.8 (market cap $73.22B), while BIO-TECHNE Corp trades at $71.75 (market cap $11.14B). The key difference: EOG Resources Inc is far larger — about 6.6× BIO-TECHNE Corp's market cap, and EOG Resources Inc pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| EOG | TECH | |
|---|---|---|
Market Cap | $73.22B | $11.14B |
Sector | Energy | Health |
52-Week High | $149.89 | $71.48 |
52-Week Low | $101.78 | $43.31 |
Enterprise Value | $77.68B | $11.22B |
Dividend Yield | 2.97% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $139.12, up 0.8% on the day, with a bullish technical outlook supported by moving averages and key resistance at $140. The company maintains strong profitability with a 23.39% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EOG's valuation discount and operational strength, with a consensus price target of $156.40 suggesting 12% upside.
EOG presents a compelling investment case with solid fundamentals, consistent earnings beats, and positive analyst sentiment, though risks include oil price volatility and elevated capital expenditures. The stock's current valuation below historical averages offers a margin of safety for long-term investors seeking exposure to a high-quality energy producer.
Bio-Techne (TECH) trades at $71.69, up 0.65% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, though RSI indicates potential overbought conditions. Fundamentally, revenue held at $1.22B in 2025, but net income fell to $73.40M with margin compression. Analysts are split 50/50 buy/hold with a $67.75 consensus target, below the current price, reflecting acquisition uncertainty.
The outlook hinges on the Merck deal closure at $73.00, offering a 1.8% premium from current levels. Risks include shareholder litigation challenging the transaction's fairness and regulatory approval delays. Without the deal, high P/E of 102.12 and declining profitability pose downside risks. The acquisition provides a near-term floor, but execution volatility remains a concern for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
